Choose License Type
The global airway stent/lung stent market was valued at USD 80.00 million in 2018. The growing incidence of lung cancer coupled with rising prevalence of chronic respiratory diseases across the globe, along with the rising demand for minimally invasive procedures, are some of the factors that lead to this market's development. The related difficulty with utilizing such stents, and a rise in the availability of alternative drugs could impede market development.
Stents and tubular devices are conventionally used in treating malignant congestion to preserve the patency of the airways and are rarely seen in benign diseases. Malignant airway obstruction typically occurs from direct bronchogenic carcinoma activity, resulting from expansion of carcinomas that arise in the esophagus resulting thyroid. External squeezing of lymph nodes or metastatic disease of other organs may also cause central obstruction of the airways.
Growing R&D spending for the development of non-vascular stents by public as well as private organizations is further likely to accelerate demand for lung stents in coming years. For eg., in the U.S. in January 2020, the FDA licensed 3D printed airway stents. Cleveland Clinic performed this study, and it is projected that about 30,000 stents will be implanted in the U.S. alone before the end of 2020. This indicates the possible need in the immediate future for lung stents. However, the availability of other alternative treatments and usage-related problems can impact the use of such stents.
Key segments of the global airway stent/lung stent market
Type Overview, 2015-2025 (USD Million)
Material Overview, 2015-2025 (USD Million)
Product Overview, 2015-2025 (USD Million)
End User Overview, 2015-2025 (USD Million)
Regional Overview, 2015-2025 (USD Million)
Reasons for the study
· Rising incidence of COPD, and lung cancer
· Focus on the development of drug eluting stents
What does the report include?
Who should buy this report?
Consultants, analysts, researchers, and academicians looking for insights shaping the global airway stent/lung stent market
Many thoracic surgeons and interventional pulmonologists often use airway stents treat certain reflexive reactions. The reflexive reactions are the product of previous traumatic events, or are profoundly rooted by their teachers in their psychology. When this occurs, it is important to examine the clinical case critically, the alternatives available for that individual patient and the solid evidence behind the biomaterials and engineering of current airway stents. Stent positioning is only granted a few total contramaterials. In addition, people who are legally willing to perform surgical operations to treat benign or malignant diseases do not have an external prothesis of the airway.
The global market is segmented on the basis of material, type, end use, and product. The material segment is further broken down to metal, silicone, and hybrid. The metal segment is further broken down into nitinol stents, stainless steel stents, and others. In 2018, metal stents dominated the global market due to its low migration rates, ease of implantation. Additionally, in terms of type, tracheobronchial segment dominated the global market on account of its high adoption rates amongst medical practitioners.
Rising preference of surgeons for expandable stents rather than non-expandable ones is adding to their dominant market share as of 2018. Additionally, the benefit of its usage such as ease of placement, small size and low chance of stent-induced complications further drive the market for expandable stents over the forecast period.
On the basis of region, the global market is classified into North America, Europe, Asia Pacific, Central & South America, and Middle East and Africa. As of 2018, North America's airway stent industry accounted for the dominant share compared to other regional markets, and is projected to retain its domination throughout the forecast period. The presence of large scale suppliers, well-established healthcare facilities, and high recognition among the surgeons culminated in this region's growing acceptance of such stents.
On the other hand, Asia Pacific is likely to emerge as the most lucrative regional market on account of improving reimbursement scenario in countries such as China and India. Growing prevalence of COPD and lung carcinoma amongst adults is likely to favor the market growth in coming years. Key players in the market include Boston Scientific Corporation, Cook Medical, Taewoong Medical Co., Ltd., Merit Medical Systems, Inc., Benson Hood Laboratories, Inc, and many more.
The global airway stent/lung stent market was valued at USD 80.00 million in 2018. The growing incidence of lung cancer coupled with rising prevalence of chronic respiratory diseases across the globe, along with the rising demand for minimally invasive procedures, are some of the factors that lead to this market's development. The related difficulty with utilizing such stents, and a rise in the availability of alternative drugs could impede market development.
Stents and tubular devices are conventionally used in treating malignant congestion to preserve the patency of the airways and are rarely seen in benign diseases. Malignant airway obstruction typically occurs from direct bronchogenic carcinoma activity, resulting from expansion of carcinomas that arise in the esophagus resulting thyroid. External squeezing of lymph nodes or metastatic disease of other organs may also cause central obstruction of the airways.
Growing R&D spending for the development of non-vascular stents by public as well as private organizations is further likely to accelerate demand for lung stents in coming years. For eg., in the U.S. in January 2020, the FDA licensed 3D printed airway stents. Cleveland Clinic performed this study, and it is projected that about 30,000 stents will be implanted in the U.S. alone before the end of 2020. This indicates the possible need in the immediate future for lung stents. However, the availability of other alternative treatments and usage-related problems can impact the use of such stents.
Key segments of the global airway stent/lung stent market
Type Overview, 2015-2025 (USD Million)
Material Overview, 2015-2025 (USD Million)
Product Overview, 2015-2025 (USD Million)
End User Overview, 2015-2025 (USD Million)
Regional Overview, 2015-2025 (USD Million)
Reasons for the study
· Rising incidence of COPD, and lung cancer
· Focus on the development of drug eluting stents
What does the report include?
Who should buy this report?
Consultants, analysts, researchers, and academicians looking for insights shaping the global airway stent/lung stent market
1. Introduction
1.1. Introduction
1.2. Market Definition and Scope
1.3. Units, Currency, Conversions and Years Considered
1.4. Key Stakeholders
1.5. Key Questions Answered
2. Research Methodology
2.1. Introduction
2.2. Data Capture Sources
2.3. Market Size Estimation
2.4. Market Forecast
2.5. Data Triangulation
2.6. Assumptions and Limitations
3. Market Outlook
3.1. Introduction
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.2.4. Challenges
3.3. Porter’s Five Forces Analysis
4. Airway Stent/Lung Stent Market by Type, 2015-2025 (USD Million)
4.1. Tracheobronchial Stents
4.2. Laryngeal Stents
5. Airway Stent/Lung Stent Market by Material, 2015-2025 (USD Million)
5.1. Metal Stents
5.1.1. Stainless Steel Stents
5.1.2. Nitinol Stents
5.1.3. Others
5.2. Silicone Stents
5.3. Hybrid Stents
6. Airway Stent/Lung Stent Market by Product, 2015-2025 (USD Million)
6.1. Non-Expandable
6.2. Self-Expandable
7. Airway Stent/Lung Stent Market by End User, 2015-2025 (USD Million)
7.1. Hospitals
7.2. Ambulatory Surgery Centers
8. Airway Stent/Lung Stent Market by Region 2015-2025 (USD Million)
8.1. North America
8.1.1. U.S.
8.1.2. Canada
8.2. Europe
8.2.1. UK
8.2.2. Germany
8.2.3. France
8.2.4. Rest of Europe
8.3. Asia Pacific
8.3.1. China
8.3.2. Japan
8.3.3. India
8.3.4. Rest of APAC
8.4. Latin America
8.4.1. Brazil
8.4.2. Mexico
8.4.3. Rest of Latin America
8.5. Middle East & Africa
9. Competitive Landscape
9.1. Company Ranking
9.2. Market Share Analysis
9.3. Strategic Initiatives
9.3.1. Mergers & Acquisitions
9.3.2. New Type Launch
9.3.3. Investments
9.3.4. Expansion
9.3.5. Others
10. Company Profiles
10.1. Merit Medical Systems, Inc.
10.1.1. Overview
10.1.2. Types Portfolio
10.1.3. Recent Initiatives
10.1.4. Company Financials
10.2. Boston Scientific Corporation
10.3. Taewoong Medical Co., Ltd.
10.4. Micro-Tech (Nanjing) Co., Ltd.
10.5. Bess Aktiengesellschaft (Bess AG)
10.6. Efer Endoscopy
10.7. Standard Sci. Tech Inc.
10.8. E. Benson Hood Laboratories, Inc.
11. Appendix
11.1. Primary Research Approach
11.1.1. Primary Interview Participants
11.1.2. Primary Interview Summary
11.2. Questionnaire
11.3. Related Reports
11.3.1. Published
11.3.2. Upcoming